IP Verse

Bioverativ Therapeutics competitive analysis

Loading summary...

Latest oppositions filed by Bioverativ Therapeutics

Explore patent oppositions filed by Bioverativ Therapeutics against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 23, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3225233
Sodium Chloride Solution For Drug Reconstitution Or DilutionWYETHMay 14, 2020
EP2256135
Proteolytically Cleavable Fusion Protein Comprising A Blood Coagulation FactorCSL BEHRINGDec 13, 2019
EP2482841
Compositions And Methods For Enhancing Coagulation Factor Viii FunctionTHE CHILDRENS HOSPITAL OF PHILADELPHIAAug 21, 2019

Latest patents of Bioverativ Therapeutics opposed by its competitors

Explore Bioverativ Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2956477
Jan 24, 2024Optimized Factor Viii Gene1
EP2870250
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof2

Latest publications and patents of Bioverativ Therapeutics New

Explore the latest publications and patents granted to Bioverativ Therapeutics, showcasing their recent innovations and technological advancements.

Last updated on: Oct 18, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Bioverativ Therapeutics

EP2956477
Jan 24, 2024Optimized Factor Viii GenePatent Maintained As Amended
EP2870250
Jun 29, 2022Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses ThereofPatent Maintained As Amended

Latest PTAB cases involving Bioverativ Therapeutics

Discover the latest PTAB cases involving Bioverativ Therapeutics, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Bioverativ Therapeutics

IPR2018-01345Jul 6, 2018CSL BEHRINGBIOVERATIV THERAPEUTICSInstitution Denied
IPR2018-01313Jul 2, 2018CSL BEHRINGBIOVERATIV THERAPEUTICSInstitution Denied

Peer Comparison New

IP litigation analysis comparing Bioverativ Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOVERATIV THERAPEUTICS33 - 2
CSL BEHRING394 -
EUROPEAN OPPOSITIONS30 - - -
FH SERVICES7 - - -